Aaron B Beasley
Overview
Explore the profile of Aaron B Beasley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
193
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Denisenko E, de Kock L, Tan A, Beasley A, Beilin M, Jones M, et al.
Nat Commun
. 2024 Apr;
15(1):2860.
PMID: 38570491
High-grade serous ovarian carcinoma (HGSOC) is genetically unstable and characterised by the presence of subclones with distinct genotypes. Intratumoural heterogeneity is linked to recurrence, chemotherapy resistance, and poor prognosis. Here,...
2.
Acheampong E, Allsopp R, Page K, Wadsley M, Beasley A, Coombes R, et al.
Clin Chem
. 2024 Jan;
70(1):234-249.
PMID: 38175603
Background: Programmed death ligand-1 (PD-L1) expression on circulating tumor cells (CTCs) has been suggested to provide prognostic information in non-small cell lung cancer (NSCLC), but consensus relative to treatment outcomes...
3.
Beasley A, Preen D, McLenachan S, Gray E, Chen F
Invest Ophthalmol Vis Sci
. 2023 Nov;
64(14):2.
PMID: 37910093
Purpose: The purpose of this study was to estimate the incidence and mortality of conjunctival melanoma in Australia from 1982 to 2014. Methods: De-identified unit data for all cases of...
4.
Beasley A, de Bruyn D, Calapre L, Al-Ogaili Z, Isaacs T, Bentel J, et al.
J Cancer Res Clin Oncol
. 2023 Aug;
149(16):14953-14963.
PMID: 37608028
Background: Approximately 50% of uveal melanoma (UM) patients will develop metastatic disease depending on the genetic features of the primary tumour. Patients need 3-12 monthly scans, depending on their prognosis,...
5.
Carlessi R, Denisenko E, Boslem E, Kohn-Gaone J, Main N, Abu Bakar N, et al.
Cell Genom
. 2023 May;
3(5):100301.
PMID: 37228755
Current approaches to staging chronic liver diseases have limited utility for predicting liver cancer risk. Here, we employed single-nucleus RNA sequencing (snRNA-seq) to characterize the cellular microenvironment of healthy and...
6.
Asante D, Mohan G, Acheampong E, Ziman M, Calapre L, Meniawy T, et al.
Sci Rep
. 2023 Feb;
13(1):2552.
PMID: 36781954
Circulating tumour cells (CTCs) are heterogenous and contain genetic information from the tumour of origin. They bear specific intra- and extra-cellular protein markers aiding in their detection. However, since these...
7.
Medhin L, Beasley A, Warburton L, Amanuel B, Gray E
Semin Cancer Biol
. 2023 Jan;
89:92-98.
PMID: 36706847
Melanoma is the most aggressive form of skin cancer owing to its high propensity to metastasise in distant organs and develop resistance to treatment. The scarce treatment options available for...
8.
Calapre L, Giardina T, Beasley A, Reid A, Stewart C, Amanuel B, et al.
Sci Rep
. 2023 Jan;
13(1):278.
PMID: 36609632
Plasma circulating tumour DNA (ctDNA) has been suggested to be a viable biomarker of response to treatment in patients with high grade serous ovarian carcinoma (HGSOC). TP53 mutations are present...
9.
Acheampong E, Morici M, Abed A, Bowyer S, Asante D, Lin W, et al.
J Cancer Res Clin Oncol
. 2022 Jul;
149(5):1941-1950.
PMID: 35896898
Background: Circulating tumour cells (CTCs) are attractive "liquid biopsy" candidates that could provide insights into the different phenotypes of tumours present within a patient. The epithelial-to-mesenchymal transition (EMT) of CTCs...
10.
Acheampong E, Abed A, Morici M, Spencer I, Beasley A, Bowyer S, et al.
Transl Lung Cancer Res
. 2022 Apr;
11(3):440-451.
PMID: 35399573
Background: Antibodies against the programmed death-1 (PD-1) receptor and its ligand (PD-L1) have been recently approved for small-cell lung cancer (SCLC) treatment. Circulating tumour cells (CTCs) have emerged as an...